Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2018 · 10-Q
Revenue$2.30M$2.30M−27.3% vs Q3 2017 Net Income-$1.86M-$1.86MN/M vs Q3 2017 EPS Diluted-$0.04-$0.04N/M vs Q3 2017 Gross Profit$512,545+21.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$883,289+30.3% Free Cash Flowderived$879,939+32.8% Margins · derivedGross margin22.3%+9.0 pt vs Q3 2017
Operating margin-84.0%−19.0 pt vs Q3 2017
Net margin-80.8%−11.3 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end